Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Neutral 54.6%

Neg 0% Neu 54.6% Pos 0%

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.